期刊
CURRENT NEUROPHARMACOLOGY
卷 13, 期 6, 页码 776-785出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1570159X13666151102103305
关键词
Alzheimer's disease; arachidonic acid; autism spectrum disorder; cyclooxygenases-1 inhibitors; cyclooxygenases-2 inhibitors; depression; eicosanoids; schizophrenia
Arachidonic acid (AA)-derived lipid mediators are called eicosanoids. Eicosanoids have emerged as key regulators of a wide variety of physiological responses and pathological processes, and control important cellular processes. AA can be converted into biologically active compounds by metabolism by cyclooxygenases (COX). Beneficial effect of COXp2 inhibitor celecoxib addpon therapy has been reported in early stage of schizophrenia. Moreover, addpon treatment of celecoxib attenuated refractory depression and bipolar depression. Further, the COX/prostaglandin E pathway play an important role in synaptic plasticity and may be included in pathophysiology in autism spectrum disorders (ASD). In this regard, plasma transferrin, which is an iron mediator related to eicosanoid signaling, may be related to social impairment of ASD. COXp2 is typically induced by inflammatory stimuli in the majority of tissues, and the only isoform responsible for propagating the inflammatory response. Thus, COXp2 inhibitors considered as the best target for Alzheimer's disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据